IMCAS Academy

Presentación
Programa
Oradores
Listado de sponsors
Acreditación

VOLVER

IMCAS Asia 2023
Programa

FOCO EN S104

CONTRIBUTING LECTURES - Clinical dermatology & Dermatologic surgery

Sala: Room 4
Fecha: domingo 11 junio 2023 de 15:00 a 16:00
Formato: CONTRIBUTIVA > presentaciones que fueron cuidadosamente revisadass y seleccionadas por el Consejo Científico. basadas en presentaciones y/o resúmenes recibidos

Moderadores

Dr Hugues CARTIER

Dermatólogo

Francia

Dr Peter Wee Beng CH ' NG

Dermatólogo

Malasia

Las presentaciones

Horas	Oradores	Título de la presentación	Resumen	Número
15:00	Dr Shanthala SHIVANANJAPPA	Exosomes and energy based treatments for acne scar managment: my experience	Ver	127278
15:12	Dr Jiayi FENG	Clinical analysis and treatment of 64 cases of acute contact dermatitis caused by compound lidocaine cream	Ver	124013
15:24	Dr Lisa Kwin Wah CHAN	Innovative scar treatment with IPL	Ver	125423
15:36		Q&A		124008

Ver sesiones anteriores

Ver la sala siguiente (Room 5)

Sesiones recomendadas

Cicatrices

Acné

Exosomas

Queloídes

Sistemas de luz (IPL, UV, IR, LED...)

Dr Shanthala SHIVANANJAPPA

Médico

Estados Unidos

Otro(s) autor(es) :

Exosomes and energy based treatments for acne scar managment: my experience

Objectives: This abstract discusses the potential benefits of exosomes as an adjuvant therapy with standard first-line energy-based treatments for severe acne scar remodeling. Atrophic acne scars with severe underlying fibrosis can be very challenging to treat, especially in the forehead, and temple areas, and is even harder in darker skin types. Exosomes, are small lipid bi-layered nanovesicles loaded with growth factors, nucleotides, proteins, and lipids that have shown promising improvement in wound healing, scar remodeling can offer synergistic benefits in the optimal correction of acne scars.

Introduction: Acne scars are the most common troublesome chronic inflammatory skin condition that leads to scarring and hyperpigmentation. Post-acne sequelae can have a significant impact on a person's self-esteem and quality of life. While traditional treatments such as peels, microdermabrasion, dermabrasion, subcision, laser therapy, and RF micro needling have shown some success in improving the appearance of acne scars, there is a growing interest in the use of exosomes as adjuvant therapy for these treatments. Exosomes offer excellent anti-inflammatory benefits in the treatment of acne scar revision.

Materials / method: We reviewed acne scar patients who received exosome and EBD combo therapy for 3 years from 2020 to 2023. These patients had all types of acne scars with various stages, depth, fibrosis, with or without erythema and hyperpigmentation. This was a 3 step procedure. All of them had subcision, followed by FRF or 1550 or both then had topical application of exosomes. Patients with forehead or temple scars with severe atrophy had microdisection/ hydrodisection with exosomes using 32g 4 mm needle instead of subcision. Finally LLLT was used to enhance the absorption of exosomes.

Results: The majority of our patients noticed a significant reduction in acne-related redness or erythema, and acne-induced hyperpigmentation without having vascular or PICO lasers. My patients reported high levels of satisfaction, brightening effect, and smoothness of the skin. Almost all of them had shorter recovery times and minimal side effects such as post-laser PIE and PIH especially in darker skin groups.

Conclusion: Exosomes offer a powerful anti-inflammatory, regenerative benefit that can synergistically work with energy-based treatments in patients with difficult or severe acne scarring. The exosomes reducing chronic inflammation, their effect on all 4 phases of wound healing, and reduction of erythema and pigmentation can be great adjuvant therapy for both the prevention and treatment of acne scars. The cell-free Exosomes adjuvant therapy with EBDs can be the future in preventing and treating acne scars, especially in high-risk SOC patients and severe acne scars with erythema and pigmentation.

Declaraciones

¿Ha recibido algún tipo de financiamiento para realizar su investigación sobre esta temática?
No

¿Ha recibido algún pago, honorario u otra compensación por su trabajo acerca de esta investigación?
No

¿Tiene vínculos financieros con alguna entidad que podría llegar a competir estrechamente con los medicamentos, materiales o instrumentos tratados en su investigación?
No

¿Posee o ha solicitado una patente relacionada a los materiales, productos o instrumentos utilizados en su investigación?
No

Este trabajo no cuenta con el apoyo de ningún financiamiento directo o indirecto. El autor asume plena responsabilidad sobre el mismo.

Dr Jiayi FENG

Cirujano Plástico

China

Otro(s) autor(es) : Lvping Huang

Clinical analysis and treatment of 64 cases of acute contact dermatitis caused by compound lidocaine cream

Objectives: 1. Diagnosis of lidocaine induced dermatitis and grading of severity.

2. How to treat the patients according to the standard grading therapy set by us according to the severity of mild, moderate and severe.

3. Characteristics of lidocaine induced dermatitis and ways to reduce its occurrence.

Introduction: Topical anesthesia with compound lidocaine cream has become a routine analgesic method before photoelectric therapy. However, due to individual differences, there is the possibility of mild or severe adverse reactions when using compound lidocaine cream for external use, which will affect the follow-up laser treatment, but also cause skin trauma to patients, leading to downtime and subsequent complications. For medical institutions, it is easy to produce disputes.

Materials / method: 64 patients with skin allergy caused by compound lidocaine cream before facial photoelectric treatments in the laser aesthetic center of our hospital from March to August 2022 were analyzed retrospectively. The analysis included the history of skin allergy, the site of skin lesions. Moreover, according to the severity of skin lesions were divided into mild, moderate and severe, the corresponding standard treatment was carried out as well.

Results: During the observation period, a total of 6709 patients with compound lidocaine cream were treated before treatments, 64 patients developed allergic reaction (0.9%).Under our graded standardized treatment, the mild and moderate patients were basically cured within 2 weeks, 2 cases were left with color deposition. The severe patients were basically cured within 1 month, and there was no residual color deposition.

Conclusion: The skin state of patients should be observed before external use of lidocaine cream, and the skin changes of patients should be paid attention to at any time in the process of external use, especially for the high-risk areas prone to allergy. With early detection, our graded standardized treatment can reduce the skin injury after the allergies. The recovery time can be obviously shortened and the risk of color subsidence can be reduced.

Declaraciones

¿Ha recibido algún tipo de financiamiento para realizar su investigación sobre esta temática?
No

¿Ha recibido algún pago, honorario u otra compensación por su trabajo acerca de esta investigación?
No

¿Tiene vínculos financieros con alguna entidad que podría llegar a competir estrechamente con los medicamentos, materiales o instrumentos tratados en su investigación?
No

¿Posee o ha solicitado una patente relacionada a los materiales, productos o instrumentos utilizados en su investigación?
No

Este trabajo no cuenta con el apoyo de ningún financiamiento directo o indirecto. El autor asume plena responsabilidad sobre el mismo.

Dr Lisa Kwin Wah CHAN

Médico

Hong Kong

Otro(s) autor(es) : Dr. Lee Cheuk Hung, Dr. Alvin Lee

Innovative scar treatment with IPL

Objectives: IPL can improve the appearance of keloid, hypertrophic and macular scars by reducing their size, thickness and redness. Multiple sessions may be necessary. IPL is a safe and well-tolerated treatment, and it could be combined with other treatment modalities like intra-lesional steroids.

Introduction: Scarring can be a distressing experience for patients. In this study, we aimed to evaluate the efficacy and safety of Intense Pulsed Light (IPL) treatment for Chinese patients with macular, hypertrophic, and keloid scars. By examining the effectiveness of this treatment approach, we hope to provide patients with a safe and effective option to scar treatment.

Materials / method: This study evaluated IPL treatment for 6 patients with macular, hypertrophic, and keloid scars on different body areas. IPL treatment included cutoff filters of 515-755nm, pulse durations of 3-6ms, pulse delay of 10-40ms, fluence of 10-22 J/cm2, double and triple pulses, and 10-18 treatment sessions. The treatments were performed tri-weekly until patients were satisfied with the cosmetic results, with no adjuvant therapy given. Clinical photos were taken before each treatment, with patient satisfaction rates and side effects monitored.

Results: In all 6 patients, there was a significant clinical improvement in hyperpigmentation, thickness, hardness, and redness of the scars, with an overall improvement rate of 100%. Excellent improvement was observed in five patients (83%), while the remaining patient showed good improvement. The effects of IPL treatments were long-lasting, and all patients reported high levels of satisfaction with the treatment outcomes

Conclusion: Our study suggests that Intense Pulsed Light (IPL) therapy is an effective treatment option for improving the erythema, hardness, thickness, and appearance of scars resulting from a variety of causes. The results of the treatment were observed to be long-lasting, indicating the potential of IPL therapy as a promising approach for managing scars.

Declaraciones

¿Ha recibido algún tipo de financiamiento para realizar su investigación sobre esta temática?
No

¿Ha recibido algún pago, honorario u otra compensación por su trabajo acerca de esta investigación?
No

¿Tiene vínculos financieros con alguna entidad que podría llegar a competir estrechamente con los medicamentos, materiales o instrumentos tratados en su investigación?
No

¿Posee o ha solicitado una patente relacionada a los materiales, productos o instrumentos utilizados en su investigación?
No

Este trabajo no cuenta con el apoyo de ningún financiamiento directo o indirecto. El autor asume plena responsabilidad sobre el mismo.

Q&A

¿Tiene una pregunta?

Encuentre las respuestas rápidamente en nuestra sección de FAQ.

Congresos

IMCAS Americas
IMCAS Asia
IMCAS World Congress

Acerca de

Empresa
Política de Confidencialidad
Mención legal

Academy

Inicio
Cursos
Webinars
Explorar
Blog

Subvenciones

Subvención educativa

Ponerse en contacto

Contáctenos

Nombre de usuario/Email

Contraseña

Mantenerme conectado

Iniciar sesión

Olvidé mi contraseña ? Todavía no tiene una cuenta? Inscríbase ahora

Mantenerme conectado

academy.Do_not_have_an_account_yet Inscríbase ahora

IMCAS Asia 2023 Programa

FOCO EN S104

CONTRIBUTING LECTURES - Clinical dermatology & Dermatologic surgery

Moderadores

Las presentaciones

Sesiones recomendadas

IMCAS Asia 2023
Programa